ArticleBritish journal of pharmacology2019

Oral administration of a new HRI activator as a new strategy to improve high-fat-diet-induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21.

Mohammad Zarei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.